Abiopharma

🔍 PAUL STEVEN M (Executive)

Company: Seaport Therapeutics, Inc. (SPTX)

Report Date: 2026-04-30

Detailed Transactions and Holdings:

• Acquired 67,031 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: C | equity_swap_involved: false | shares_owned_after: 863,031.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 12,258 shares of Stock Option (Right to Buy) at $18.0 per share (Derivative)
  Date: 2026-04-30 | Code: A | Expires: 2036-04-29 | equity_swap_involved: false | shares_owned_after: 12,258.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 991,192 shares of Stock Option (Right to Buy) at $18.0 per share (Derivative)
  Date: 2026-04-30 | Code: A | Expires: 2036-04-29 | Exercise: 2026-04-30 | equity_swap_involved: false | shares_owned_after: 991,192.00 | transaction_form_type: 4
• Sold 67,031 shares of Series B Preferred Stock (Derivative)
  Date: 2026-05-04 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
• F2: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.